$20.47
-1.40-6.4%
Last update: Nov 3, 4:04 AM
Structure Therapeutics Inc (GPCR) Stock Price, Quote, News & History
GPCRNASDAQ
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.
You can purchase shares of Structure Therapeutics (NASDAQ:GPCR) through any online brokerage.
Other companies in Structure Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Structure Therapeutics has a consensus price target of $98.40.
The stock price for Structure Therapeutics (NASDAQ: GPCR) is $20.35 last updated November 3, 2026 at 4:04 AM EST.
There are no upcoming dividends for Structure Therapeutics.
Structure Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Structure Therapeutics.
Structure Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both...
